

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

DIAGNOSTICS ASSESSMENT PROGRAMME

Equality impact assessment – Scoping

Tests in secondary care to identify people at high risk of ovarian cancer

The impact on equality has been assessed during this assessment according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (scoping workshop discussion, assessment subgroup discussion), and, if so, what are they?

During scoping it was noted that people with cancer are protected under the Equality Act 2010 from the point of diagnosis.

The Simple Rules system and the ADNEX model are not recommended for use with people who are pregnant. This is because changes to the endometrium that occur during pregnancy can alter the appearance of lesions and affect the characterisation features required by both these tests. The levels of serum markers used in included tests such as CA125 can also be affected by pregnancy.

The ROMA has not been validated for use with people under 18 years and the OVA2/Overa test is not recommended for use in people under 18 years. In addition, it was suggested that the use of transvaginal ultrasound probes may not be appropriate in this group.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee, including patient experts, should consider the use of these tests in children and people who are pregnant when making recommendations.

The Committee will also consider whether its recommendations could have a

different impact on people protected by the equality legislation than on the wider population

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders have been identified.

Approved by Associate Director (name): ...Carla Deakin.....

Date: 8 November 2016